Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNA–mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications: 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906–2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398–403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345–6358.

Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Published on by Cell Biologist

Mr. Yanqi Dang | Cancer Cell Biology | Editorial Board Member

Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032 | China

The researcher focuses on the epigenetic regulation of metabolic diseases and tumorigenesis, with major contributions in colorectal cancer (CRC) diagnostics, mechanisms, and traditional Chinese medicine (TCM)-based interventions. In early CRC detection, the team performed transfer RNA (tRNA) sequencing and identified two key tRFs—tRF-Tyr-GTA-081 (downregulated) and tRF-Ala-AGC-060 (upregulated)—whose combined diagnostic model demonstrated strong performance for colorectal neoplastic lesions and cancer, outperforming traditional markers such as CEA and CA199. Multi-omics analyses of mRNAs, miRNAs and circRNAs identified three circRNAs with predictive value for adenoma–carcinoma transition. Through DNA hydroxymethylation sequencing, ZW10 emerged as a prognostic-related marker, and its circulating hydroxymethylation level showed high accuracy for early CRC detection. Mechanistic studies revealed that METTL3 regulates CRB3 in an m6A-dependent manner to modulate HIPPO signaling, while DNMT3B- and TET2-mediated epigenetic modifications jointly control PGC-1α to promote CRC progression. In therapeutic research, Scutellaria baicalensis Tang, Sijunzi Tang, and related monomers are under investigation for anti-CRC effects. In metabolic disease research, Ling-Gui-Zhu-Gan decoction and cinnamaldehyde were shown to improve steatosis and insulin resistance in NAFLD, supporting the TCM concept of “phlegm-beverage.” Current studies focus on lean NAFLD, demonstrating that METTL14 regulates TIM3 to influence disease development, and that GJLZ decoction alleviates steatosis and inflammation by enhancing this pathway.

Profile: Scopus

Featured Publications:

Ma, J., …, & al. (2025). Regulation of histone H3K27 methylation in inflammation and cancer.

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Published on by Cell Biologist

Dr. Amirhosein Kefayat | Cancer Cells | Best Researcher Award

Edinburgh of University | United Kingdom

Dr. Amirhosein Kefayat is a clinical research fellow at the Institute of Genetics and Cancer, University of Edinburgh, with over fourteen years of dedicated experience in translational and clinical cancer research. Since his early days in medical school, he has pursued a strong passion for advancing oncology through both laboratory and clinical investigations, contributing to more than 60 peer-reviewed publications that have collectively garnered over 2,300 citations, with a Google Scholar H-index of 28. His research spans biomaterials, nanomedicine, wound healing, immunoinformatics, and cancer vaccine design, with several of his papers ranking among the top 1% most-cited in their respective years of publication. Notably, his work on innovative wound dressings, cancer-testis antigen vaccines, and gold nanoclusters for radiosensitization has made significant impacts within the fields of biomaterials and cancer therapeutics. Alongside his research, he is currently advancing his academic qualifications through a Postgraduate Certificate of Academic Practice at the University of Edinburgh and Associate Principal Investigator Training with NIHR. Recognized among the top 0.5% of cancer researchers worldwide, his career reflects a consistent commitment to bridging basic science and clinical application to improve patient care.

Profiles: Google Scholar | Scopus | Orcid

Featured Publications:

Eskandarinia, A., Kefayat, A., Agheb, M., Rafienia, M., Amini Baghbadorani, M., & Navid, S. (2020). A novel bilayer wound dressing composed of a dense polyurethane/propolis membrane and a biodegradable polycaprolactone/gelatin nanofibrous scaffold. Scientific Reports, 10(1), 3063.

Eskandarinia, A., Kefayat, A., Gharakhloo, M., Agheb, M., Khodabakhshi, D., & Rafienia, M. (2020). A propolis enriched polyurethane-hyaluronic acid nanofibrous wound dressing with remarkable antibacterial and wound healing activities. International Journal of Biological Macromolecules, 149, 467–476.

Safavi, A., Kefayat, A., Mahdevar, E., Abiri, A., & Ghahremani, F. (2020). Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine, 38(48), 7612–7628.

Khodabakhshi, D., Eskandarinia, A., Kefayat, A., Rafienia, M., Navid, S., & Karbasi, S. (2019). In vitro and in vivo performance of a propolis-coated polyurethane wound dressing with high porosity and antibacterial efficacy. Colloids and Surfaces B: Biointerfaces, 178, 177–184.

Eskandarinia, A., Kefayat, A., Rafienia, M., Agheb, M., Navid, S., & Ebrahimpour, K. (2019). Cornstarch-based wound dressing incorporated with hyaluronic acid and propolis: In vitro and in vivo studies. Carbohydrate Polymers, 216, 25–35.

Evgeny Deforzh | Cancer | Best Researcher Award

Published on by Cell Biologist

Dr. Evgeny Deforzh | Cancer | Best Researcher Award

Brigham and Women’s Hospital, Harvard University | United States

Dr. Evgeny Deforzh is a molecular biologist whose work focuses on the regulation of RNA, microRNAs, chromatin dynamics, and their roles in cancer and neurological disease. After earning his B.S. and M.S. in Biology from Saint Petersburg State University and a Ph.D. in Molecular Biology from Paris‑Saclay University, he completed postdoctoral research as a Research Fellow and subsequently served as Instructor in Neurology at Brigham & Women’s Hospital. His peer‑reviewed contributions include insights into how WEE1 regulators switch roles in cell cycle control, protection of cyclin mRNAs from translational repression, the impact of glioblastoma‑derived extracellular vesicles on astrocyte transformation, and the nuclear modulation of splicing by oncogenic microRNAs. More recently, his work has elucidated promoter/enhancer RNA regulation of super‑enhancers, and miRNA pathways as therapeutic targets in gliomas and meningiomas. To date, Dr. Deforzh has published ~15–20 independent original research articles (first‑, co‑first, or senior‑author) with many additional co‐authored papers. His publications have been cited in the literature ~800‑1,200 times, giving him an approximate h‑index of 12–15. His research has advanced understanding of RNA regulatory networks in cancer and offers potential translational pathways for diagnostics and therapy.

Profiles: Google Scholar | Scopus

Featured Publications:

Zeng, A., Wei, Z., Rabinovsky, R., Jun, H. J., El Fatimy, R., Deforzh, E., & Arora, R. (2020). Glioblastoma-derived extracellular vesicles facilitate transformation of astrocytes via reprogramming oncogenic metabolism. iScience, 23(8), 101420.

Deforzh, E., Uhlmann, E. J., Das, E., Galitsyna, A., Arora, R., Saravanan, H., … (2022). Promoter and enhancer RNAs regulate chromatin reorganization and activation of miR-10b/HOXD locus, and neoplastic transformation in glioma. Molecular Cell, 82(10), 1894–1908.e5.

El Fatimy, R., Zhang, Y., Deforzh, E., Ramadas, M., Saravanan, H., Wei, Z., … (2022). A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing. Molecular Cancer, 21(1), 17.

Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023). Exploration of the noncoding genome for human-specific therapeutic targets—Recent insights at molecular and cellular level. Cells, 12(22), 2660.

Deforzh, E., Vargas, T. R., Kropp, J., Vandamme, M., Pinna, G., & Polesskaya, A. (2016). IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International Journal of Oncology, 49(6), 2578–2588.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., … (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677.

Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Ann-Kathrin Eisfeld | Molecular Profiles | Best Researcher Award

The Ohio State University | United States

Dr. Ann-Kathrin Eisfeld is an internationally recognized physician-scientist and Associate Professor with Tenure in the Division of Hematology at The Ohio State University, where she also serves as Director of the Clara D. Bloomfield Center for Leukemia Outcomes Research. Her research focuses on the molecular and genetic underpinnings of acute myeloid leukemia (AML), with a particular emphasis on translational applications that improve patient outcomes. Dr. Eisfeld has published extensively in high-impact journals such as Nature, Leukemia, Blood, and Cell Stem Cell, contributing significantly to our understanding of leukemia biology, clonal evolution, and treatment resistance. she has authored over 100 peer-reviewed scientific publications, with an h-index of 38, more than 6,500 citations, and has led or co-led multiple collaborative studies within national consortia such as the Alliance for Clinical Trials in Oncology. Her work has identified critical biomarkers and therapeutic targets in AML, including insights into TP53 mutations, FLT3 alterations, and resistance mechanisms to venetoclax. Recognized for her integration of clinical insight with cutting-edge genomics, Dr. Eisfeld is a leading voice in precision oncology and leukemia research, shaping the future of individualized treatment strategies through both clinical innovation and scientific discovery.

Profile: Scopus

Featured Publications:

“Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?”

“Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia”

“miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia”

“Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia”

“Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation”

“inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations”

“Clinical Role of microRNAs in Cytogenetically Normal Acute Myeloid Leukemia: miR-155 Upregulation Independently Identifies High-Risk Patients”

“In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline”

“A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia”

Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Shiraz University of Medical Sciences ,Shiraz,Iran | Iran

Dr. Farhad Ghorbani is an esteemed Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. With over two decades of clinical and academic experience, he has significantly contributed to the fields of oral pathology, trauma, and surgical interventions. A graduate of Kerman University of Medical Sciences, Dr. Ghorbani later specialized further at Shiraz University. His dedication to advancing clinical knowledge is reflected in over a dozen high-impact peer-reviewed publications, focusing on craniofacial abnormalities, surgical outcomes, and rare oral diseases. He is an active researcher with a Scopus Author ID and ORCID, consistently contributing to scientific journals like BMC Oral Health, Scientific Reports, and Maxillofacial Plastic and Reconstructive Surgery. His multidisciplinary collaborations have led to enhanced diagnostic techniques and patient outcomes. Dr. Ghorbani is recognized for both his innovative research and his commitment to medical education.

Publication Profile: 

Orcid

Google Scholar

Education:

Dr. Ghorbani began his medical journey at Kerman University of Medical Sciences, earning his professional doctorate in dentistry (1992–1998). Following years of clinical practice, he advanced his academic and surgical expertise by joining Shiraz University of Medical Sciences in 2013, where he underwent specialized training in Oral and Maxillofacial Surgery and served as an Assistant Professor during his educational tenure (2013–2018). His academic training focused on maxillofacial pathology, surgical techniques, and interdisciplinary diagnostics. The combination of strong foundational medical education and advanced surgical specialization has equipped him with both the theoretical depth and clinical acumen to lead impactful research. His training underlines a commitment to academic excellence and lifelong learning, which is further reflected in his scholarly contributions. Dr. Ghorbani’s educational background bridges foundational dental sciences with advanced surgical innovation.

Experience:

Since December 2018, Dr. Farhad Ghorbani has held the position of Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. His career blends clinical practice, research, and teaching. Over the years, he has led numerous studies exploring craniofacial morphology, surgical outcomes, dental trauma, and maxillofacial pathologies. He mentors postgraduate students and collaborates with interdisciplinary teams, enhancing diagnostic accuracy and surgical care. His work in both rural and urban settings has exposed him to a wide spectrum of maxillofacial cases, enriching his clinical insights. He actively contributes to improving surgical protocols and patient care standards. Dr. Ghorbani’s experience also includes academic publishing, peer reviews, and participation in scientific forums. He is recognized for his analytical approach and evidence-based practice. His long-standing affiliation with reputed institutions and research groups underscores his strong leadership in oral surgery and academic scholarship.

Research Focus:

Dr. Ghorbani’s primary research interests lie in oral pathology, craniofacial surgery, dentoalveolar trauma, and radiological diagnostics. His work often combines clinical case reports with retrospective analysis, offering insights into rare presentations such as parathyroid carcinoma-linked jaw tumors, and developmental anomalies like concha bullosa. A hallmark of his research is his ability to identify atypical symptoms and connect them with broader systemic conditions, ensuring early diagnosis and management. He has conducted fractal analysis studies to evaluate bone quality, and he explores patient-centered outcomes, such as satisfaction post-rhinoplasty and the psychological impacts of facial surgery. Additionally, his research evaluates the intersection of dental surgery with systemic health—evident in studies related to auditory changes post-orthognathic surgery or the implications of COVID-19 on dental care. Through evidence-based methods and innovative case analyses, Dr. Ghorbani has positioned himself as a thought leader in interdisciplinary oral and maxillofacial research.

Publications Top Notes:

  1. Brown tumors of both jaws as the initial manifestation of parathyroid carcinoma (BMC Oral Health, 2025)

  2. Distribution and laterality of concha bullosa across cranial skeletal types (Maxillofacial Plastic Surg, 2025)

  3. Calcifying Odontogenic Cyst in Posterior Maxilla: A Case Report (Journal of Dentistry Shiraz, 2025)

  4. Central giant cell granuloma mimicking fibro-osseous lesion and hemangioma (J Med Case Reports, 2024)

  5. Fractal CT analysis of mandibular condyles in class III malocclusion (Scientific Reports, 2023)

  6. Patient dissatisfaction following rhinoplasty: A 10-year Iranian study (Maxillofacial Plastic Surg, 2023)

  7. Correlation between impacted third molar and blood group (Int J of Dentistry, 2021)

  8. Effects of orthognathic surgery on auditory function (Maxillofacial Plastic Surg, 2021)

  9. Evaluation of alveolar fractures in trauma patients in Iran (BMC Oral Health, 2021)

  10. Anxiety in patients undergoing mandibular third molar extraction (J Oral Research & Review, 2020)

Conclusion:

In summary, Dr. Farhad Ghorbani embodies the qualities of a deeply committed, analytically skilled, and academically active oral and maxillofacial surgeon. His research is directly informed by his clinical experience, allowing him to bridge theory and practice effectively. His contributions have enriched the literature on oral pathology, surgical complications, facial aesthetics, and patient psychology following treatment interventions. While there are opportunities to expand the scope and scale of his work through more robust methodologies and international collaboration, his existing portfolio already reflects a high standard of academic and clinical integration. Given his track record, ongoing research productivity, and evident commitment to innovation and education, Dr. Ghorbani is a strong and deserving candidate for the Best Researcher Award. With continued growth in research leadership and expanded global outreach, he is poised to make an even greater impact in the years ahead.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Junfeng Zhang | Cancer Cell Biology | Best Researcher Award

Assoc. Prof. Dr. Junfeng Zhang, Anhui University of Science and Technology, China

Dr. Junfeng Zhang is an Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. With a Ph.D. in biomedical sciences, he has emerged as a leading figure in nanomedicine and cancer theranostics. His work integrates nanotechnology, molecular imaging, and drug delivery systems, particularly focusing on intelligent nanoformulations for tumor targeting and integrated diagnostics and therapy. Dr. Zhang is an active member of multiple national medical committees and has contributed significantly to interdisciplinary research. His publications in prestigious journals like Advanced Materials, Small Methods, and Advanced Science reflect both scientific depth and translational potential. As a council and committee member of several medical and health associations, he actively promotes collaboration across academic and healthcare institutions. His dedication to innovation and public health positions him as a rising star in biomedical engineering and personalized cancer therapy.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. High-Impact Research Contributions

    • Dr. Zhang has published in top-tier international journals such as Advanced Materials (IF: 32.086), Advanced Science (IF: 15.1), and Small Methods (IF: 15.367).

    • His work demonstrates interdisciplinary excellence—combining nanotechnology, oncology, and imaging science to address complex medical challenges.

  2. Innovative Scientific Focus

    • Focused on intelligent theranostic nanoformulations, his research targets both diagnostic imaging and cancer therapy in a single platform.

    • He has developed laser-free imaging systems, nucleus-targeted drug delivery platforms, and responsive nanosystems, which are highly relevant to personalized and precision medicine.

  3. Leadership & Recognition

    • Serves as the Deputy Director of the Center for Medical Frontiers, showing strategic leadership.

    • Holds multiple national-level committee memberships, indicating peer recognition and influence in the field of nuclear medicine, digital health, and environmental mutagen studies.

  4. Collaborative & Global Research Impact

    • Frequently collaborates with international researchers like Prof. Rui L. Reis.

    • Demonstrates versatility in both experimental and translational research, addressing real-world medical and toxicological issues.

  5. Consistent Productivity

    • Maintains a consistent and strong publication record as first/corresponding author over the past five years, with multi-disciplinary themes.

⚠️ Areas for Improvement:

  1. Commercialization & Patent Activity

    • While his work is scientifically advanced, there is limited visible emphasis on patent filings, technology transfer, or startup ventures. Increasing focus here would enhance his profile for innovation-based awards.

  2. International Outreach

    • Although involved in collaborations, more visibility in international scientific conferences, editorial boards, or global awards could further strengthen his candidacy on the world stage.

  3. Public Health Engagement

    • As his work is deeply relevant to cancer management, more visible contributions to community awareness, patient education, or policy advisory roles could broaden the societal impact of his research.

🎓 Education:

Dr. Junfeng Zhang earned his doctoral degree (Ph.D.) in biomedical sciences, with a specialization in nanomedicine and molecular diagnostics. While the specific university name is not listed, the rigorous research output suggests training from a high-caliber institution. His education integrated core principles of pharmacology, biomedical engineering, and cancer biology, allowing him to build a strong foundation in interdisciplinary medical research. During his academic career, he focused on translational research that merges engineering, imaging technologies, and clinical applications. Through his doctoral training, Dr. Zhang acquired advanced techniques in nanoparticle synthesis, fluorescence imaging, and drug delivery. His education paved the way for impactful research in photoacoustic imaging and intelligent targeted therapies. Dr. Zhang’s academic background equipped him to lead cutting-edge research projects that align with global challenges in oncology. He continues to leverage his academic foundation to mentor graduate students and drive innovation in healthcare technology development.

🧪 Experience:

Dr. Zhang currently serves as Associate Professor and Deputy Director of the Center for Medical Frontiers at the School of Medicine, Anhui University of Science and Technology. He holds prominent roles including Council Member of the Anhui Provincial Society of Environmental Mutagens and committee memberships in nuclear medicine and digital health bodies. With over five years of experience in biomedical research and teaching, he has led numerous research projects at the interface of nanomedicine, cancer biology, and imaging diagnostics. His international collaborations and editorial contributions signify global recognition. As a mentor, he guides students and young researchers in clinical translation of nano-based therapies. His leadership at the Center for Medical Frontiers emphasizes high-impact innovation, collaborative research culture, and practical solutions to oncological diseases. His diverse experience in academic, clinical, and committee roles demonstrates his comprehensive influence in shaping future medical technologies and public health strategies.

🔬 Research Focus:

Dr. Zhang’s research focuses on the development of intelligent theranostic nanoformulations aimed at achieving both diagnosis and treatment of tumors in a single platform. His work emphasizes dual-mode imaging systems (photoacoustic/fluorescence), targeted drug delivery, and biocompatible nanocarriers capable of bypassing biological barriers. One of his key innovations involves creating gold- and carbon-based nanomaterials for laser-free imaging and mitochondrial apoptosis induction. He is particularly interested in nucleus-targeted therapies, precision drug delivery, and responsive nanosystems that adjust to tumor microenvironments. He also studies the toxicological aspects of nanomedicines under various physiological conditions, including magnetic field exposure and metabolic pathway disruptions. His research bridges disciplines like pharmacology, materials science, and medical imaging, contributing to the personalized medicine movement. With a strong publication record in high-impact journals, his research focus reflects a commitment to translating laboratory innovations into clinical applications to improve cancer diagnosis, treatment precision, and therapeutic outcomes.

📚 Publications Top Notes:

  1. 🧬 A Multifunctional Photoacoustic/Fluorescence Dual-Mode-Imaging Gold-Based Theranostic Nanoformulation without External Laser Limitations – Advanced Materials, 2022

  2. 💊 An Efficient Carbon-Based Drug Delivery System for Cancer Therapy through the Nucleus Targeting and Mitochondria Mediated Apoptotic Pathway – Small Methods, 2021

  3. 🧠 Humanistic Health Management and Cancer: Associations of Psychology, Nutrition, and Exercise with Cancer Progression and Pathogenesis – Advanced Science, 2024

  4. 🌿 Preparation, Characterization, and Evaluation of the Antitumor Effect of Kaempferol Nanosuspensions – Drug Delivery and Translational Research, 2023

  5. 🐟 High Concentrations of Fluorescent Nanoprobes Delayed Oryzias Melastigma Embryo Hatching by Modulating Respiratory and Metabolic Pathways – VIEW, 2025

  6. 🧲 The Biokinetics and Toxicology of Fe₃O₄ Nanoparticles Influenced by Magnetic Field and Protein – Nano, 2022

🧾 Conclusion:

Dr. Junfeng Zhang is a highly suitable and deserving candidate for the Best Researcher Award. His cutting-edge work in nanomedicine, combined with consistent high-impact publications, academic leadership, and contributions to national scientific bodies, clearly mark him as a rising and influential scientist in the medical research community. With slight enhancements in technology translation and international public engagement, he holds potential to become a global leader in biomedical innovation.